tirzepatide europe approval EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above Lilly Receives European Marketing Authorization

At weight loss doses, semaglutide produces notably higher rates of every major GI symptom

A meta-analysis covering over 28,000 patients found that while the overall rate of GI adverse events was similar (approximately 5253% of patients in both groups), serious adverse events occurred somewhat more frequently with higher tirzepatide doses (5.37% at 1015 mg) compared to semaglutide (2.8%)

The placebo group reported hair loss at roughly 1%

For some people, the dosages that are mass produced by manufacturers dont work for certain individuals, which can make using those types of tirzepatide injections much less effective for them

Compounded Medications are not reviewed or approved by the FDA